

**Final Draft Agenda**  
**33<sup>rd</sup> meeting of the Committee for Socio-economic Analysis**

**29 November – 2 December 2016**  
**ECHA Conference Centre (Annankatu 18, Helsinki)**

**29 November starts at 9.00**  
**2 December ends at 13.30**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

**SEAC/A/33/2016**  
**For adoption**

**Item 3 – Declarations of conflicts of interest to the Agenda**

**For information**

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on SEAC-32 action points, written procedures and update on other ECHA bodies

**SEAC/33/2016/01**  
**For information**

**Item 5 – Restrictions**

**5.1 Restriction Annex XV dossiers**

- a) Conformity check
  - 1) Diisocyanates – outcome of the conformity check and presentation of the key issues

**For agreement**

b) Opinion development

- 1) TDFAs – second draft opinion
- 2) 4 phthalates – second draft opinion

***For discussion***

**5.2 Appointment of (co-)rapporteurs for restriction dossiers**

***For information***

**Item 6 – Authorisation**

**6.1 General authorisation issues**

a) Update on incoming/future applications

***For information***

b) Report on AfA Task Force and related activities

***For information***

c) Harmonisation of AfA opinions

***For discussion***

d) Boundaries of socio-economic analysis in applications for authorisation

***SEAC/33/2016/02***

***For discussion***

**6.2 Authorisation applications**

a) Outcome of the conformity check and presentation of the key issues

1. CT\_Hapoc\_2 (1 use)
2. CT\_Hapoc\_3 (1 use)
3. CT\_Haas (1 use)
4. SD\_Haas (1 use)
5. PD\_Haas (1 use)
6. CT\_Reachlaw (4 uses)
7. CT\_Clariant (1 use)
8. CT\_ZFL (2 uses)
9. SD\_ZFL (1 use)
10. CT\_Cryospace (1 use)
11. SC\_Aviall (2 uses)
12. SD\_Borealis (1 use)
13. SD\_Ormezzano (2 uses)
14. AD\_BAE (2 uses)
15. EDC\_Biotech (1 use)
16. EDC\_ORGAPHARM (2 uses)
17. EDC\_Akzo (1 use)
18. EDC\_Bayer (1 use)
19. EDC\_Olon (2 uses)
20. MOCA\_Reachlaw (1 use)

***For agreement***

b) Agreement on draft opinions

1. Diglyme\_Merck (1 use)
2. Diglyme\_Isochem (1 use)
3. Diglyme\_Roche (1 use)
4. Diglyme\_LifeTech (1 use)
5. Diglyme\_Acton (2 uses)
6. Diglyme\_Bracco (1 use)
7. Diglyme\_Maflon (1 use)
8. Chromium trioxide\_HAPOC (4 uses) (CT\_HAPOC)
9. EDC\_ELI LILLY S.A. (1 use) (EDC\_Eli\_Lilly)
10. Potassium dichromate GENTROCHEMA BV (2 uses)  
(PD\_Gentrochema)
11. Sodium dichromate GENTROCHEMA BV (3 uses)  
(SD\_Gentrochema)

***For discussion and agreement***

c) Adoption of final opinions

1. Chromium trioxide\_Cromomed (1 use) (CT\_Cromomed)
2. Chromium trioxide\_Burscheid (1 use) (CT\_Burscheid)
3. Chromium trioxide\_Friedberg (1 use) (CT\_Friedberg)
4. Chromium trioxide\_Valvetrain (1 use) (CT\_Valvetrain)
5. Sodium dichromate\_Akzo (2 uses) (SD\_Akzo)
6. Sodium dichromate\_Arkema (1 use) (SD\_Arkema)
7. Chromic acid\_Bosch (1 use) (CA\_Bosch)
8. Potassium dichromate\_Brenntag (2 uses) (PD\_Brenntag)
9. Sodium dichromate\_Brenntag (3 uses) (SD\_Brenntag)
10. Dichromium tris(chromate)\_Henkel (2 uses) (DtC\_Henkel)
11. Strontium chromate\_Akzo (2 uses) (ST\_Akzo)
12. Potassium hydroxyoctaoxidizincatedichromate\_PPG (2 uses) (PH\_PPG)

***For discussion and adoption***

**6.3 Appointment of (co-)rapporteurs for authorisation applications  
(closed session)**

***SEAC/33/2016/03  
(restricted room document)  
For agreement***

**Item 7 – AOB**

a) Update of the work plan

***For information***

**Item 8 – Action points and main conclusions of SEAC-33**

Table with Conclusions and Action points from SEAC-33

***For adoption***

